Published in BJU Int on August 13, 2014
Prostate cancer diagnosis and treatment after the introduction of prostate-specific antigen screening: 1986-2005. J Natl Cancer Inst (2009) 6.07
Active surveillance program for prostate cancer: an update of the Johns Hopkins experience. J Clin Oncol (2011) 5.27
Do adenocarcinomas of the prostate with Gleason score (GS) ≤6 have the potential to metastasize to lymph nodes? Am J Surg Pathol (2012) 3.05
Comparing the Gleason prostate biopsy and Gleason prostatectomy grading system: the Lahey Clinic Medical Center experience and an international meta-analysis. Eur Urol (2008) 2.77
A tertiary Gleason pattern in the prostatectomy specimen and its association with adverse outcome after radical prostatectomy. J Urol (2014) 2.76
Pathological outcomes in men with low risk and very low risk prostate cancer: implications on the practice of active surveillance. J Urol (2013) 2.66
Outcomes of active surveillance for men with intermediate-risk prostate cancer. J Clin Oncol (2010) 2.65
Poorly differentiated prostate cancer treated with radical prostatectomy: long-term outcome and incidence of pathological downgrading. J Urol (2006) 2.50
The contemporary concept of significant versus insignificant prostate cancer. Eur Urol (2011) 2.29
Performance characteristics of MR imaging in the evaluation of clinically low-risk prostate cancer: a prospective study. Radiology (2012) 1.74
Upgrading and downgrading of prostate needle biopsy specimens: risk factors and clinical implications. Urology (2007) 1.67
Outcomes of initially expectantly managed patients with low or intermediate risk screen-detected localized prostate cancer. BJU Int (2012) 1.62
Optimization of initial prostate biopsy in clinical practice: sampling, labeling and specimen processing. J Urol (2013) 1.53
Prevalence of prostate cancer on autopsy: cross-sectional study on unscreened Caucasian and Asian men. J Natl Cancer Inst (2013) 1.32
Prostate biopsy clinical and pathological variables that predict significant grading changes in patients with intermediate and high grade prostate cancer. BJU Int (2008) 1.31
The significance of modified Gleason grading of prostatic carcinoma in biopsy and radical prostatectomy specimens. Virchows Arch (2006) 1.25
The impact of anatomical radical retropubic prostatectomy on cancer control: the 30-year anniversary. J Urol (2012) 1.24
Prostate cancer overdiagnosis and overtreatment. Curr Opin Endocrinol Diabetes Obes (2013) 1.14
Gene expression pathways of high grade localized prostate cancer. Prostate (2011) 1.12
A multi-institutional evaluation of active surveillance for low risk prostate cancer. J Urol (2013) 1.05
Defining the threshold for significant versus insignificant prostate cancer. Nat Rev Urol (2013) 1.00
Active surveillance: patient selection. Curr Opin Urol (2013) 0.98
Multiple cores of Gleason score 6 correlate with favourable findings at radical prostatectomy. BJU Int (2013) 0.82
Factors associated with downgrading in patients with high grade prostate cancer. Urol Oncol (2011) 0.81
Integrative genomic profiling of human prostate cancer. Cancer Cell (2010) 23.61
The surgical learning curve for prostate cancer control after radical prostatectomy. J Natl Cancer Inst (2007) 6.12
NCCN clinical practice guidelines in oncology: prostate cancer. J Natl Compr Canc Netw (2010) 5.98
Postoperative nomogram predicting the 10-year probability of prostate cancer recurrence after radical prostatectomy. J Clin Oncol (2005) 4.89
Radical prostatectomy: long-term cancer control and recovery of sexual and urinary function ("trifecta"). Urology (2005) 4.71
Preoperative nomogram predicting the 10-year probability of prostate cancer recurrence after radical prostatectomy. J Natl Cancer Inst (2006) 4.14
Defining biochemical recurrence of prostate cancer after radical prostatectomy: a proposal for a standardized definition. J Clin Oncol (2006) 4.05
Effects of pathologic stage on the learning curve for radical prostatectomy: evidence that recurrence in organ-confined cancer is largely related to inadequate surgical technique. Eur Urol (2008) 3.93
Metastasis after radical prostatectomy or external beam radiotherapy for patients with clinically localized prostate cancer: a comparison of clinical cohorts adjusted for case mix. J Clin Oncol (2010) 3.76
Prostate cancer-specific mortality after radical prostatectomy for patients treated in the prostate-specific antigen era. J Clin Oncol (2009) 3.74
Long-term outcomes of patients with lymph node metastasis treated with radical prostatectomy without adjuvant androgen-deprivation therapy. Eur Urol (2013) 3.65
Predicting 15-year prostate cancer specific mortality after radical prostatectomy. J Urol (2011) 3.36
Location, extent and number of positive surgical margins do not improve accuracy of predicting prostate cancer recurrence after radical prostatectomy. J Urol (2009) 3.24
Comparative effectiveness of prostate cancer surgical treatments: a population based analysis of postoperative outcomes. J Urol (2010) 3.18
Contemporary open and robotic radical prostatectomy practice patterns among urologists in the United States. J Urol (2012) 3.12
A randomized trial of robot-assisted laparoscopic radical cystectomy. N Engl J Med (2014) 2.98
Prediction of significant prostate cancer diagnosed 20 to 30 years later with a single measure of prostate-specific antigen at or before age 50. Cancer (2010) 2.90
The role of SPINK1 in ETS rearrangement-negative prostate cancers. Cancer Cell (2008) 2.87
Best practices in robot-assisted radical prostatectomy: recommendations of the Pasadena Consensus Panel. Eur Urol (2012) 2.84
Standard versus limited pelvic lymph node dissection for prostate cancer in patients with a predicted probability of nodal metastasis greater than 1%. J Urol (2007) 2.75
Systematic review and meta-analysis of perioperative outcomes and complications after robot-assisted radical prostatectomy. Eur Urol (2012) 2.74
Counseling men with prostate cancer: a nomogram for predicting the presence of small, moderately differentiated, confined tumors. J Urol (2003) 2.72
Do margins matter? The prognostic significance of positive surgical margins in radical prostatectomy specimens. J Urol (2005) 2.69
Salvage radical prostatectomy for radiation-recurrent prostate cancer: a multi-institutional collaboration. Eur Urol (2011) 2.63
Surgeon experience is strongly associated with biochemical recurrence after radical prostatectomy for all preoperative risk categories. J Urol (2008) 2.57
Do margins matter? The prognostic significance of positive surgical margins in radical prostatectomy specimens. J Urol (2008) 2.57
International validation of a preoperative nomogram for prostate cancer recurrence after radical prostatectomy. J Clin Oncol (2002) 2.51
Poorly differentiated prostate cancer treated with radical prostatectomy: long-term outcome and incidence of pathological downgrading. J Urol (2006) 2.50
Systematic review and meta-analysis of studies reporting potency rates after robot-assisted radical prostatectomy. Eur Urol (2012) 2.43
TMPRSS2-ERG gene fusion is not associated with outcome in patients treated by prostatectomy. Cancer Res (2009) 2.42
Prostate cancer, version 2.2014. J Natl Compr Canc Netw (2014) 2.40
Prostate-specific antigen at or before age 50 as a predictor of advanced prostate cancer diagnosed up to 25 years later: a case-control study. BMC Med (2008) 2.39
B7-H3 and B7x are highly expressed in human prostate cancer and associated with disease spread and poor outcome. Proc Natl Acad Sci U S A (2007) 2.37
Secondary therapy, metastatic progression, and cancer-specific mortality in men with clinically high-risk prostate cancer treated with radical prostatectomy. Eur Urol (2007) 2.30
Pathological upgrading and up staging with immediate repeat biopsy in patients eligible for active surveillance. J Urol (2008) 2.22
Extent of pelvic lymph node dissection and the impact of standard template dissection on nomogram prediction of lymph node involvement. Eur Urol (2011) 2.22
Risk of incisional hernia after minimally invasive and open radical prostatectomy. J Urol (2013) 2.18
Pathological features of lymph node metastasis for predicting biochemical recurrence after radical prostatectomy for prostate cancer. J Urol (2012) 2.15
A critical analysis of the long-term impact of radical prostatectomy on cancer control and function outcomes. Eur Urol (2011) 2.11
Urinary pH is highly associated with tumor recurrence during intravesical mitomycin C therapy for nonmuscle invasive bladder tumor. J Urol (2011) 2.07
Pretreatment prostate-specific antigen (PSA) velocity and doubling time are associated with outcome but neither improves prediction of outcome beyond pretreatment PSA alone in patients treated with radical prostatectomy. J Clin Oncol (2009) 2.05
Impact of smoking status on bladder tumor recurrence after radical nephroureterectomy for upper tract urothelial carcinoma. J Urol (2013) 2.05
A multi-institutional evaluation of active surveillance for low risk prostate cancer. J Urol (2009) 1.97
A preoperative nomogram identifying decreased risk of positive pelvic lymph nodes in patients with prostate cancer. J Urol (2003) 1.96
Prognostic significance of Bacillus Calmette-Guérin failure classification in non-muscle-invasive bladder cancer. BJU Int (2012) 1.93
Variations among experienced surgeons in cancer control after open radical prostatectomy. J Urol (2010) 1.93
Role of prostate specific antigen and immediate confirmatory biopsy in predicting progression during active surveillance for low risk prostate cancer. J Urol (2010) 1.91
Predicting biochemical recurrence-free survival for patients with positive pelvic lymph nodes at radical prostatectomy. J Urol (2010) 1.88
Prostate cancer, Version 3.2012: featured updates to the NCCN guidelines. J Natl Compr Canc Netw (2012) 1.84
Improved toxicity profile following high-dose postprostatectomy salvage radiation therapy with intensity-modulated radiation therapy. Eur Urol (2011) 1.81
Contemporary use of partial nephrectomy at a tertiary care center in the United States. J Urol (2009) 1.78
Performance characteristics of MR imaging in the evaluation of clinically low-risk prostate cancer: a prospective study. Radiology (2012) 1.74
Endorectal MR imaging before salvage prostatectomy: tumor localization and staging. Radiology (2006) 1.69
Pelvic lymph node dissection during robot-assisted radical prostatectomy: efficacy, limitations, and complications-a systematic review of the literature. Eur Urol (2013) 1.69
Germline BRCA mutations denote a clinicopathologic subset of prostate cancer. Clin Cancer Res (2010) 1.68
Prognostic impact of positive surgical margins in surgically treated prostate cancer: multi-institutional assessment of 5831 patients. Urology (2005) 1.63
Androgen deprivation and thromboembolic events in men with prostate cancer. Cancer (2011) 1.62
Acupuncture in the treatment of upper-limb lymphedema: results of a pilot study. Cancer (2013) 1.62
Oncologic outcome and patterns of recurrence after salvage radical prostatectomy. Eur Urol (2008) 1.61
Comparison of CT urography and excretory urography in the detection and localization of urothelial carcinoma of the upper urinary tract. AJR Am J Roentgenol (2011) 1.61
Routine drain placement after partial nephrectomy is not always necessary. J Urol (2011) 1.61
Interobserver variability of R.E.N.A.L., PADUA, and centrality index nephrometry score systems. World J Urol (2014) 1.55
Robotic-assisted prostatectomy: is there truth in advertising? Eur Urol (2008) 1.55
The prognostic significance of capsular incision into tumor during radical prostatectomy. Eur Urol (2010) 1.53
The Prostate Cancer Prevention Trial risk calculator and the relationship between prostate-specific antigen and biopsy outcome. Cancer (2013) 1.52
A case-mix-adjusted comparison of early oncological outcomes of open and robotic prostatectomy performed by experienced high volume surgeons. BJU Int (2013) 1.51
Comprehensive standardized report of complications of retropubic and laparoscopic radical prostatectomy. Eur Urol (2009) 1.50
Is it necessary to remove the seminal vesicles completely at radical prostatectomy? decision curve analysis of European Society of Urologic Oncology criteria. J Urol (2008) 1.50
Prostatic transition zone directed needle biopsies uncommonly sample clinically relevant transition zone tumors. J Urol (2009) 1.49
Prognostic role of KiSS-1 and possibility of therapeutic modality of metastin, the final peptide of the KiSS-1 gene, in urothelial carcinoma. Mol Cancer Ther (2012) 1.47
Achieving optimal outcomes after radical prostatectomy. J Clin Oncol (2005) 1.46
Locally advanced prostate cancer: a population-based study of treatment patterns. BJU Int (2011) 1.46
Radical prostatectomy for clinically localized, high risk prostate cancer: critical analysis of risk assessment methods. J Urol (2007) 1.45
The clinical significance of urine cytology after a radical cystectomy for urothelial cancer. Int J Urol (2010) 1.43
Comprehensive prospective comparative analysis of outcomes between open and laparoscopic radical prostatectomy conducted in 2003 to 2005. J Urol (2008) 1.43
Validation study of a web-based assessment of functional recovery after radical prostatectomy. Health Qual Life Outcomes (2010) 1.42
Is interval from an initial biopsy a significant predictor of prostate cancer at repeat biopsies? Int J Urol (2006) 1.41
Current recommendations for delaying renal transplantation after localized prostate cancer treatment: are they still appropriate? Transplantation (2004) 1.41
The prognostic utility of preoperative neutrophil-to-lymphocyte ratio in localized clear cell renal cell carcinoma. Can J Urol (2016) 1.41
Accuracy of post-radiotherapy biopsy before salvage radical prostatectomy. BJU Int (2013) 1.40
Positive posterior margin of needle biopsy cores is an independent predictor for extracapsular extension in retropubic radical prostatectomy. Urology (2013) 1.39
Can transrectal needle biopsy be optimised to detect nearly all prostate cancer with a volume of ≥0.5 mL? A three-dimensional analysis. BJU Int (2013) 1.39
The natural history of noncastrate metastatic prostate cancer after radical prostatectomy. Eur Urol (2006) 1.38
Association of cysteine-rich secretory protein 3 and beta-microseminoprotein with outcome after radical prostatectomy. Clin Cancer Res (2007) 1.38
Impact of routine use of surgical drains on incidence of complications with robot-assisted radical prostatectomy. J Endourol (2014) 1.38
High-intensity focused ultrasound for prostate cancer: comparative definitions of biochemical failure. BJU Int (2009) 1.36
Radical prostatectomy in men aged >or=70 years: effect of age on upgrading, upstaging, and the accuracy of a preoperative nomogram. BJU Int (2008) 1.35
Long-term outcome following radical prostatectomy in men with clinical stage T3 prostate cancer. J Urol (2006) 1.35
Metastatic renal cell carcinoma risk according to tumor size. J Urol (2009) 1.35
Pattern of prostate-specific antigen (PSA) failure dictates the probability of a positive bone scan in patients with an increasing PSA after radical prostatectomy. J Clin Oncol (2005) 1.35
Positive surgical margins in radical prostatectomy: outlining the problem and its long-term consequences. Eur Urol (2008) 1.35